NGM Biopharmaceuticals and MedImmune, AstraZeneca's Biologics Arm, Announce Agreement to Discover and Develop Therapies for

 NGM Biopharmaceuticals and MedImmune, AstraZeneca's Biologics Arm, Announce
     Agreement to Discover and Develop Therapies for Diabetes and Obesity

PR Newswire

SOUTH SAN FRANCISCO, Calif., June 17, 2013

SOUTH SAN FRANCISCO, Calif., June 17, 2013 /PRNewswire/ -- NGM
Biopharmaceuticals, Inc. and MedImmune, the global biologics research and
development arm of AstraZeneca, announced today that they have entered into an
exclusive agreement to discover, develop and commercialize novel therapeutics
from NGM's enteroendocrine cell (EEC) program for the treatment of type 2
diabetes and obesity.

EECs represent less than 1% of all gastrointestinal (GI) cells, but produce
virtually all of the known GI hormones, including GLP-1. EECs are an
underexplored source of novel hormones that could play a major role in the
positive and negative regulation of metabolism and glucose homeostasis. NGM
has established a proprietary platform capable of isolating and analyzing EECs
in order to identify novel secreted peptide hormones that are potentially
linked to the profound metabolic effects of bariatric surgery and serve as
potential targets for the treatment of metabolic diseases.

MedImmune and NGM will jointly advance first-in-class peptide and antibody
drug candidates based on the discovered EEC hormones. MedImmune will have the
option to license in these EEC targets, and will be responsible for the global
development, manufacture and commercialization of compounds resulting from the
collaboration.

"We believe that hormones found in the gastrointestinal tract can play an
important role in resolving diabetes after bariatric surgery. Through NGM's
innovative research in metabolic disease, we believe our collaboration could
lead to potential innovative medicines for diabetes and obesity that will make
a difference in patients' lives," said Cristina Rondinone, Ph.D., Head of
Cardiovascular and Metabolic Disease Innovative Medicines Unit, MedImmune.
"Our partnership with NGM complements AstraZeneca's existing small and large
molecule portfolio in cardiovascular and metabolic disease, one of our core
therapy areas."

Under the terms of the agreement, MedImmune will make an upfront payment and
provide NGM research funding over the course of the collaboration. If certain
development, regulatory and commercial milestones are achieved, NGM will be
entitled to receive various payments, as well as royalties on worldwide
product sales.

"We are excited to enter into this strategic partnership with MedImmune as it
represents a unique opportunity to maximize the full complement of novel
hormones secreted by these EECs for drug discovery purposes," said Jin-Long
Chen, Ph.D., founder, president and chief scientific officer of NGM.
"Together, NGM and MedImmune will build upon the culture of scientific
excellence at both organizations. With MedImmune's deep biologics and
development expertise, we are confident that we will further enrich the
pipeline of therapies for the treatment of diabetes and obesity."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San
Francisco, California committed to the identification and development of
transformational biologics for diabetes, obesity and other cardio-metabolic
diseases. The Company is focused on discovering the next generation of
therapeutics that will fundamentally change the treatment paradigm for the
growing population of diabetes and obesity patients worldwide. NGM has
established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals and
JDRF. For more information, please visit the company's website at
www.ngmbio.com.

About MedImmune

MedImmune is the worldwide biologics research and development arm of
AstraZeneca, a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialization of small molecule
and biologic prescription medicines. MedImmune is pioneering innovative
research and exploring novel pathways across key therapeutic areas, including
respiratory, inflammation and autoimmunity; cardiovascular and metabolic
disease; oncology; neuroscience; and infection and vaccines. The MedImmune
headquarters is located in Gaithersburg, Md., one of AstraZeneca's three
global R&D centers. For more information, please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

SOURCE NGM Biopharmaceuticals, Inc.

Website: http://www.ngmbio.com
Contact: NGM Biopharmaceuticals, Inc.: Aetna Wun Trombley, Ph.D.,
+1-650-243-5555, IR@ngmbio.com; or MedImmune: Tracy Rossin, +1 301-398-1468,
rossint@medimmune.com
 
Press spacebar to pause and continue. Press esc to stop.